Crestor (Rosuvastatin) Pediatric Dosing for Children Under 12

This article is pending qualified clinical review. It is written for parents and clinicians researching pediatric statin therapy and should not replace an individualized treatment plan from the child's prescriber.

Rosuvastatin (brand name Crestor) belongs to the HMG-CoA reductase inhibitor class, which it shares with atorvastatin, simvastatin, and pravastatin. Rosuvastatin comes as an oral tablet formulated in 5 mg, 10 mg, 20 mg, and 40 mg doses. Within the United States, the FDA has approved rosuvastatin for pediatric use only in familial hypercholesterolemia (FH), excluding treatment of general high cholesterol. This narrower indication is clinically significant beyond the specific dose strengths, as use in other populations constitutes off-label prescribing and warrants a distinct risk-benefit discussion between families and their healthcare provider.

The direct answer: rosuvastatin is FDA-approved starting at age 7 for homozygous familial hypercholesterolemia (HoFH) and age 8 for heterozygous familial hypercholesterolemia (HeFH), per the current FDA-approved prescribing information. For HeFH, the typical starting dose is 5 mg once daily, with a maximum of 10 mg daily for ages 8 to 9 and 20 mg daily from age 10 onward. For HoFH ages 7 to 11, the label specifies 20 mg once daily. These are label defaults, not individualized doses, and a child's actual starting dose and titration schedule should come from the prescribing clinician based on baseline LDL-C, growth stage, and other medications.

Who this indication actually covers

Only children with a confirmed or strongly suspected diagnosis of familial hypercholesterolemia fall under the FDA pediatric approval. The label restricts pediatric use to two groups: children 8 and older with HeFH who have not reached LDL-C goals after an adequate trial of diet, and children 7 and older with HoFH. Prescribing rosuvastatin to a child under 12 for any other cause of elevated cholesterol is off-label use, and off-label pediatric statin prescribing does exist in practice. A retrospective audit of statin use across four Australian pediatric hospitals documented real-world prescribing patterns in children, including variation in indications and monitoring practices, which is a useful reminder that label criteria and everyday prescribing do not always match one-to-one (Kavey et al., statin use in Australian children, four-hospital audit). Families should ask directly whether their child's prescription is on-label FH treatment or an off-label decision, since the evidence base and monitoring expectations differ between the two.

Heterozygous FH is a genetic condition, and clinical guidelines from pediatric and cardiology bodies have recommended lipid screening in childhood, with statin consideration reserved for children whose LDL-C remains high after a documented dietary trial. HoFH is rarer and more severe, typically presenting with very high LDL-C in early childhood and a materially higher lifetime cardiovascular risk, which is why treatment in HoFH is generally started earlier and pursued more aggressively, often with specialist co-management. A genetic diagnosis through cascade testing of relatives of a known FH patient gives the most confident diagnosis; clinical criteria based on LDL-C thresholds plus a parent's confirmed diagnosis can also support a diagnosis when genetic testing is not available.

FDA-approved dosing by age and FH type

These figures reflect the FDA-approved prescribing information for rosuvastatin (Crestor). The lower ceiling in younger children reflects limited pharmacokinetic and long-term safety data below age 10, not a difference in how the drug works biologically. All doses are taken once daily as an oral tablet, with or without food. No commercial liquid formulation exists; tablets can be crushed and mixed with water for immediate administration, and some compounding pharmacies can prepare a suspension, though beyond-use dating and stability should be confirmed with the compounding pharmacist rather than assumed.

Because dosing thresholds and label language can be updated, anyone relying on exact numbers for a treatment decision should confirm against the current FDA label rather than this summary alone.

What the pediatric trial evidence shows, and its limits

The main registration evidence for pediatric rosuvastatin use in HeFH comes from a randomized, placebo-controlled trial in children and adolescents, commonly referred to in the literature as the PLUTO trial. Published trial evidence in this population has reported substantial LDL-C reductions across the 5 mg to 20 mg dose range compared with placebo, with the degree of reduction increasing with dose, and safety data over the treatment period did not show meaningful effects on growth velocity or sexual maturation during that window. This article previously cited specific percentage figures and a specific PMID for this trial; those figures require direct verification against the original journal publication before being restated as precise numbers, so they are described here in general terms rather than repeated as exact statistics.

A separately important caveat: pediatric statin trials, including this one, enrolled relatively few children under age 10. Reassurance about short-term tolerability in slightly older children does not automatically extend to a 7- or 8-year-old with the same confidence. Longer-term data on growth, puberty, and cognitive development in children who started rosuvastatin specifically (as opposed to other statins) before age 10 are limited, and clinicians are extrapolating from a thinner evidence base at that end of the age range.

What is established, what is plausible, and what is not established

Established: rosuvastatin is FDA-approved for HeFH from age 8 and HoFH from age 7, at the doses in the table above. Short-term trial evidence in pediatric HeFH populations supports meaningful LDL-C lowering.

Plausible but not firmly established in rosuvastatin specifically: long-term safety on growth, puberty, and reproductive outcomes in children who start statin therapy young. The strongest long-term follow-up data in pediatric FH come predominantly from patients started on other statins (commonly pravastatin) at an average age closer to adolescence than early childhood, so applying that reassurance directly to a 7-year-old started on rosuvastatin is an extrapolation, not a direct finding.

Not established: long-term rosuvastatin-specific safety data in children started before age 10 beyond a few years of follow-up; the effect of pediatric statin therapy on hard cardiovascular outcomes (heart attack, stroke) rather than surrogate markers like LDL-C or carotid intima-media thickness.

How titration typically works

Clinicians generally start at the lowest labeled dose and reassess response before increasing it. A common pattern described in pediatric lipid guidance is to check a fasting lipid panel around 4 weeks after starting or changing a dose, and to increase the dose if the child has not reached the individualized LDL-C target set by the prescribing clinician. For ages 8 to 9, 10 mg/day is the label ceiling. For ages 10 and older, a further increase to 20 mg/day is permitted if 10 mg is insufficient. Dose changes are generally spaced at least 4 weeks apart to allow the lipid-lowering effect to stabilize before reassessing.

If a child remains above target on the maximum labeled rosuvastatin dose, options clinicians may consider include adding ezetimibe (which has pediatric approval as an adjunct in HeFH from age 10) or referring to a pediatric lipid specialist to discuss additional therapies. These decisions depend on the individual child's LDL-C trajectory, risk factors, and tolerance, and should not be made from a general dosing guide.

Monitoring: a clinician-discussion and checkpoint framework

The framework below is organized around checkpoints, not a fixed calendar, because the right interval depends on the child's age, dose, and response. It is meant to structure a conversation with the prescriber, not to replace one.

Before starting therapy

• Confirm the diagnosis basis: genetic testing, cascade screening, or clinical LDL-C criteria plus family history.
• Baseline labs: fasting lipid panel, ALT/AST, and a baseline CK if there is any prior history of muscle symptoms.
• Baseline growth data: height, weight, BMI percentile, and Tanner stage, recorded so later changes can be judged against a real starting point.
• For any patient of reproductive potential, a documented pregnancy-risk conversation, since rosuvastatin carries fetal risk warnings on the label.
• Medication reconciliation specifically for cyclosporine and gemfibrozil, both of which are contraindicated with rosuvastatin, and for antacids, which reduce absorption if taken at the same time.

Early checkpoint (around 4 weeks after starting or after any dose change)

• Repeat fasting lipid panel to judge response.
• Repeat ALT/AST.
• Ask directly about new muscle pain, weakness, or unusual fatigue; a CK level is warranted only if symptoms are present, not routinely.

Stable-dose checkpoint (roughly every 6 to 12 months, confirm interval with the prescriber)

• Fasting lipid panel and ALT/AST.
• Height, weight, and Tanner stage, tracked on the child's own growth curve rather than compared to a population average.
• Reassessment of whether the child still meets the goal LDL-C, and whether combination therapy should be discussed if not.

Escalation or stop conditions that warrant contacting the prescriber promptly

• Height velocity dropping below the child's own established percentile trend.
• New, persistent muscle pain or weakness, especially if accompanied by dark urine.
• ALT/AST rising to a level the prescriber flags as clinically significant (the specific threshold is a clinical judgment call, not a fixed public number).
• Any suspected pregnancy in an adolescent patient.
• Persistent LDL-C above goal on the maximum labeled dose, which is a trigger for specialist referral rather than further self-directed dose increases.

Where label guidance ends and individualized care begins The FDA label sets the outer boundaries: minimum age, starting dose, and maximum dose. It does not set the exact target LDL-C for a specific child, the exact monitoring interval, or the decision to add a second lipid-lowering agent. Those are individualized clinical judgments made between the family and the treating clinician, informed by the child's baseline severity, family cardiovascular history, and tolerance of therapy. A dosing guide, including this one, can describe the label's boundaries; it cannot make the individualized decision.

Drug interactions and considerations specific to children

Cyclosporine is contraindicated with rosuvastatin at any dose. Some children under 12 take cyclosporine after solid-organ transplantation, and if a statin is needed in that setting, rosuvastatin is not an appropriate choice. Gemfibrozil is also contraindicated, since it raises rosuvastatin exposure and increases myopathy risk through inhibition of hepatic drug transport.

Rosuvastatin is labeled as carrying fetal risk, so pregnancy counseling is part of standard practice for any patient of reproductive potential, which becomes relevant as a child approaches or passes menarche. Rosuvastatin exposure is also known to run higher in patients of Asian ancestry, and the adult label reflects this with a lower recommended starting dose in that population; there is no pediatric-specific study confirming the same magnitude of effect in children, but the same general caution and closer monitoring is reasonable to discuss with the prescriber. Antacids containing aluminum or magnesium can reduce rosuvastatin absorption meaningfully if taken at the same time, so separating dosing by a couple of hours is a reasonable practical step.

Why rosuvastatin instead of another pediatric statin

Rosuvastatin is not the only statin with pediatric approval. Pravastatin is approved from age 8 for HeFH, and atorvastatin from age 10. Rosuvastatin is more potent by milligram, meaning a lower dose can achieve LDL-C lowering comparable to a higher dose of an older statin. In practice, the choice between statins in a child under 12 often depends on how far above goal the child's LDL-C is and which agent the family and prescriber feel will be easiest to adhere to long term. Rosuvastatin also undergoes minimal CYP3A4 metabolism, which can reduce interaction risk with certain antifungals and macrolide antibiotics compared with atorvastatin or simvastatin. This is a general pharmacologic comparison rather than a claim about which statin is best for any specific child, and that decision belongs with the prescribing clinician.

When a pediatric lipid specialist should be involved

A child under 12 with suspected or confirmed HoFH generally warrants referral to a lipid specialist or pediatric cardiologist with FH expertise before starting therapy, since HoFH often requires combination treatment or procedures like LDL apheresis that fall outside general pediatric practice. Other reasonable referral triggers include LDL-C that remains persistently high despite maximum labeled rosuvastatin plus ezetimibe, unexplained or clinically significant CK elevation, suspected statin intolerance on more than one agent, and any child under age 8 with severe dyslipidemia being considered for off-label statin therapy. Children with FH plus additional risk factors, such as type 1 diabetes, chronic kidney disease, or a transplant history, also generally benefit from specialist co-management alongside their regular pediatrician.

Long-term safety: what parents are really asking

Parents most often want to know whether a daily statin will affect a growing child's height, puberty, or fertility. Longer-term follow-up studies of children who started statin therapy for FH, predominantly on other statins started around early adolescence, have reported adult height and reproductive outcomes similar to unaffected siblings, along with some evidence of slowed progression of early atherosclerosis markers compared with untreated FH relatives. This is genuinely reassuring, but it is not the same as long-term rosuvastatin-specific data in children who start at age 7 or 8. Short-term adverse effects reported in pediatric statin trials mirror those in adults: headache, mild muscle aches, abdominal discomfort, and nausea in a minority of patients. Rhabdomyolysis has not been reported in the pediatric rosuvastatin trial literature but remains a theoretical risk shared across the statin class, which is part of why symptom-triggered CK monitoring matters even though routine CK checks are not required.

Practical administration notes

Rosuvastatin's half-life is roughly 19 hours, long enough that morning or evening dosing works equally well, unlike some older statins that require evening dosing for effectiveness. For children who cannot swallow pills, tablets can be crushed and mixed with water or a small amount of soft food like applesauce for immediate use; ask the pharmacist about compounded suspension options if daily crushing is impractical. Because FH is a lifelong condition with no symptoms a child can feel day to day, adherence tends to drop over time. A visual chart, a reminder app, or age-appropriate explanation of the condition ("your body makes more cholesterol than it should because of a gene you inherited, and this medicine helps protect your blood vessels") can help sustain daily use.